- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Hifibio Inc. (Hifibio Therapeutics)
Headquarters: Cambridge, MA, United States of America
Website: http://hifibio.com
Year Founded: 2013
Status: Private
BioCentury | Nov 3, 2023
Management Tracks
Prokarium hires Henry as COO
Plus: Actinium hires Bodarky and updates from Summit, CentiVax, vTv and Calidi
BioCentury | Jan 6, 2023
Management Tracks
Singhal to lead development at Biogen as company splits R&D
Plus: Baumal named CMO at Apellis, and updates from Pheast, Sofinnova Partners, GE, Lexeo and more
BioCentury | Jun 14, 2021
Product Development
June 14 Quick Takes: Biogen’s Nightstar acquisition falls flat with second gene therapy failure; plus RAPT, Terns, Amylyx, Avenue and more
Biogen Inc. (NASDAQ:BIIB) announced the company’s second late-stage failure for an ophthalmic gene therapy in the past month on Monday when the biopharma said timrepigene emparvovec
BioCentury | Jan 12, 2021
Product Development
OX40L pipeline: Data Byte
Kymab leads the pack among companies targeting OX40L for autoimmune disorders, while Moderna has the most advanced program against the target for cancer. OX40L, the ligand for the OX40 receptor,
BioCentury | Sep 5, 2020
Product Development
Sept. 4 Quick Takes: HiFiBiO in second cancer deal with Gilead; plus Bridgewest-Pfizer, Amarin, Intercept, Santhera-Idorsia, CMS, Ascendis
Gilead, HiFiBiO partner on AMLHiFiBiO Therapeutics has closed its second partnership with the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD), this time using its antibody and single-cell
BioCentury | Apr 4, 2020
Translation in Brief
HiFiBiO’s platform for antibody screening applied to COVID-19; plus Fundamental’s peptide mimetics for stroke, and BMS-IONpath
BioCentury's roundup of preclinical news
BioCentury | Aug 28, 2019
Financial News
HiFiBiO’s $67M series C attracts Kite, international syndicate
BioCentury | May 18, 2018
Finance
Ansun’s China ambitions
How Chinese series A syndicate could help Ansun crack China’s antiviral market
Items per page:
1 - 10 of 12